Following rejection and retractions, Lykos caps off chaotic week by cutting 75% of staff

[cafead]

via Lykos Therapeutics is capping off an awful week with a massive reorganization, laying off about 75% of staff in the aftermath of an FDA rejection and the retraction of three research papers on the biotech’s MDMA treatment due to protocol violations at a clinical trial site.

article source